Eran Perry
Direktor/Vorstandsmitglied bei COMPUGEN LTD.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Anat Cohen-Dayag | M | 57 | 22 Jahre | |
Alona Weiss | M | - |
I.H.C.V Israel Healthcare Ventures Ltd.
I.H.C.V Israel Healthcare Ventures Ltd. Investment ManagersFinance Israel Healthcare Ventures Ltd. (Israel Healthcare Ventures) is a venture capital firm founded in 2000 by Hadar Ron. The firm is headquartered in Tel Aviv, Israel.
Maruho Israel Innovation Fund
Maruho Israel Innovation Fund Financial ConglomeratesFinance Maruho Israel Innovation Fund engages in investments in dermatology-related technologies, biotech, medical devices, digital health, and cosmetics. The company was founded by Junichi Hamada, Eran Perry, Doron Friedman, and Masanobu Ogawa in 2018 and is headquartered in Rehovot, Israel. | 18 Jahre |
Earn Perry | M | - |
Maruho Israel Innovation Fund
Maruho Israel Innovation Fund Financial ConglomeratesFinance Maruho Israel Innovation Fund engages in investments in dermatology-related technologies, biotech, medical devices, digital health, and cosmetics. The company was founded by Junichi Hamada, Eran Perry, Doron Friedman, and Masanobu Ogawa in 2018 and is headquartered in Rehovot, Israel.
MyBiotics Pharma Ltd.
MyBiotics Pharma Ltd. BiotechnologyHealth Technology MyBiotics Pharma Ltd. operates as a micro biome pharmaceutical company that develops live bacteria based drugs. It develops MyCrobe and SuperDonor technologies for growing specific bacterial communities on pre-selected particles for stable and resistant raw material and for multi bacterial products. The company was founded in and is headquartered in Ness Ziona, Israel. | - |
Didi Daboush | M | - |
MyBiotics Pharma Ltd.
MyBiotics Pharma Ltd. BiotechnologyHealth Technology MyBiotics Pharma Ltd. operates as a micro biome pharmaceutical company that develops live bacteria based drugs. It develops MyCrobe and SuperDonor technologies for growing specific bacterial communities on pre-selected particles for stable and resistant raw material and for multi bacterial products. The company was founded in and is headquartered in Ness Ziona, Israel. | 10 Jahre |
Masha Minkin | M | - |
Noon Aesthetics Ltd.
Noon Aesthetics Ltd. Household/Personal CareConsumer Non-Durables Noon Aesthetics Ltd. is an Israeli skincare company that focuses on science-based, clinically-proven solutions to enhance the beauty and health of skin. Noon Aesthetics is based in Tel Aviv, IL and was founded in 2012 by Eran Rosman and Masha Minkin. The private company is committed to research and innovation to ensure that their products deliver tangible results and improve the overall well-being of patients. The company's products include the Restart Serum, which helps to repair DNA damage caused by oxidative stress, UV rays, air pollution, pesticides, and aging. Eran Rosman has been the CEO since 2012. | 12 Jahre |
Mathias Hukkelhoven | M | 70 | 2 Jahre | |
Masanobu Ogawa | M | - |
Maruho Israel Innovation Fund
Maruho Israel Innovation Fund Financial ConglomeratesFinance Maruho Israel Innovation Fund engages in investments in dermatology-related technologies, biotech, medical devices, digital health, and cosmetics. The company was founded by Junichi Hamada, Eran Perry, Doron Friedman, and Masanobu Ogawa in 2018 and is headquartered in Rehovot, Israel. | 6 Jahre |
Doron Friedman | M | - |
Maruho Israel Innovation Fund
Maruho Israel Innovation Fund Financial ConglomeratesFinance Maruho Israel Innovation Fund engages in investments in dermatology-related technologies, biotech, medical devices, digital health, and cosmetics. The company was founded by Junichi Hamada, Eran Perry, Doron Friedman, and Masanobu Ogawa in 2018 and is headquartered in Rehovot, Israel. | 6 Jahre |
Junichi Hamada | M | 62 |
Maruho Israel Innovation Fund
Maruho Israel Innovation Fund Financial ConglomeratesFinance Maruho Israel Innovation Fund engages in investments in dermatology-related technologies, biotech, medical devices, digital health, and cosmetics. The company was founded by Junichi Hamada, Eran Perry, Doron Friedman, and Masanobu Ogawa in 2018 and is headquartered in Rehovot, Israel. | 6 Jahre |
Sanford Zweifach | M | 68 | 6 Jahre | |
David Baram | M | - |
MyBiotics Pharma Ltd.
MyBiotics Pharma Ltd. BiotechnologyHealth Technology MyBiotics Pharma Ltd. operates as a micro biome pharmaceutical company that develops live bacteria based drugs. It develops MyCrobe and SuperDonor technologies for growing specific bacterial communities on pre-selected particles for stable and resistant raw material and for multi bacterial products. The company was founded in and is headquartered in Ness Ziona, Israel. | - |
Kinneret Livnat-Savitsky | M | 56 | 6 Jahre | |
Eran Ben-Dor | M | - | 5 Jahre | |
Zurit Levine | M | 56 | 25 Jahre | |
Yvonne Naughton | M | - | 3 Jahre | |
Eran Rosman | M | - |
Noon Aesthetics Ltd.
Noon Aesthetics Ltd. Household/Personal CareConsumer Non-Durables Noon Aesthetics Ltd. is an Israeli skincare company that focuses on science-based, clinically-proven solutions to enhance the beauty and health of skin. Noon Aesthetics is based in Tel Aviv, IL and was founded in 2012 by Eran Rosman and Masha Minkin. The private company is committed to research and innovation to ensure that their products deliver tangible results and improve the overall well-being of patients. The company's products include the Restart Serum, which helps to repair DNA damage caused by oxidative stress, UV rays, air pollution, pesticides, and aging. Eran Rosman has been the CEO since 2012. | 12 Jahre |
Gilead Halevy | M | 57 | 6 Jahre | |
Yoshinori Oikawa | M | - |
MyBiotics Pharma Ltd.
MyBiotics Pharma Ltd. BiotechnologyHealth Technology MyBiotics Pharma Ltd. operates as a micro biome pharmaceutical company that develops live bacteria based drugs. It develops MyCrobe and SuperDonor technologies for growing specific bacterial communities on pre-selected particles for stable and resistant raw material and for multi bacterial products. The company was founded in and is headquartered in Ness Ziona, Israel. | 5 Jahre |
Edd Fleming | M | - |
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 1 Jahre |
Eran Ophir | M | - | 9 Jahre | |
Marcella Ruddy | M | - |
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 1 Jahre |
Dorit Rozner | M | - |
MyBiotics Pharma Ltd.
MyBiotics Pharma Ltd. BiotechnologyHealth Technology MyBiotics Pharma Ltd. operates as a micro biome pharmaceutical company that develops live bacteria based drugs. It develops MyCrobe and SuperDonor technologies for growing specific bacterial communities on pre-selected particles for stable and resistant raw material and for multi bacterial products. The company was founded in and is headquartered in Ness Ziona, Israel. | 6 Jahre |
Paul Sekhri | M | 66 | 7 Jahre | |
Chaim Hurvitz | M | 64 |
MyBiotics Pharma Ltd.
MyBiotics Pharma Ltd. BiotechnologyHealth Technology MyBiotics Pharma Ltd. operates as a micro biome pharmaceutical company that develops live bacteria based drugs. It develops MyCrobe and SuperDonor technologies for growing specific bacterial communities on pre-selected particles for stable and resistant raw material and for multi bacterial products. The company was founded in and is headquartered in Ness Ziona, Israel. | 6 Jahre |
Chen-Ming Yu | M | 50 |
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 3 Jahre |
Dorit Amitay | F | 56 | 25 Jahre | |
Alberto Sessa | M | 61 | 2 Jahre | |
Ei Yamada | M | 74 |
MyBiotics Pharma Ltd.
MyBiotics Pharma Ltd. BiotechnologyHealth Technology MyBiotics Pharma Ltd. operates as a micro biome pharmaceutical company that develops live bacteria based drugs. It develops MyCrobe and SuperDonor technologies for growing specific bacterial communities on pre-selected particles for stable and resistant raw material and for multi bacterial products. The company was founded in and is headquartered in Ness Ziona, Israel. | 6 Jahre |
Ronald Renaud | M | 55 |
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | - |
Alex Rosen | M | - |
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 1 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Jay Radtke | M | - |
Columbia Business School
| 1 Jahre |
Elana Holzman | F | - | 4 Jahre | |
Dov Hershberg | M | 84 | 9 Jahre | |
Casey Albert | F | - |
Columbia Business School
| 3 Jahre |
Ruth Arnon | M | 91 | 11 Jahre | |
Ari Krashin | M | 51 | 8 Jahre | |
Yair Aharonowitz | M | 83 | 12 Jahre | |
Yehoshua Shemer | M | 76 | 10 Jahre | |
Eugene Song | M | - |
Columbia Business School
| 2 Jahre |
Robert Althuis | M | - |
Columbia Business School
| 1 Jahre |
Yaron Lemelbaum | M | 49 |
Columbia Business School
| 2 Jahre |
Philip Stephen Riley | M | - |
Columbia Business School
| 2 Jahre |
David Colin Getsie | M | - |
Columbia Business School
| 2 Jahre |
Erika N. Smith | F | - |
Columbia Business School
| 1 Jahre |
Gabriel Kra | M | - |
Columbia Business School
| 2 Jahre |
Yaron Sadan | M | - |
Columbia Business School
| 2 Jahre |
Julian Steinberg | M | - |
Columbia Business School
| 1 Jahre |
Gulati Mukul | M | 50 |
Columbia Business School
| 2 Jahre |
Dean B. Rostovsky | M | - |
Columbia Business School
| 2 Jahre |
Sreedhar Reddy Kona | M | - |
Columbia Business School
| 2 Jahre |
Palak S. Pathak | F | - |
Columbia Business School
| 2 Jahre |
Christopher Folkemer | M | - |
Columbia Business School
| 2 Jahre |
YangYang Liu | F | - |
Columbia Business School
| 2 Jahre |
EDWARD LEE | M | - |
Columbia Business School
| 1 Jahre |
Rose Sojung Lee | F | - |
Columbia Business School
| 2 Jahre |
Grace Kim | F | - |
Columbia Business School
| 2 Jahre |
Xiaoxu Jiang | M | 52 |
Columbia Business School
| 2 Jahre |
Rong Feng Jiang | M | 47 |
Columbia Business School
| 4 Jahre |
Jeffrey Pressman | M | - |
Columbia Business School
| 1 Jahre |
Bettina Curtze | F | 47 |
Columbia Business School
| 2 Jahre |
Linda Meehan | F | - |
Columbia Business School
| 2 Jahre |
Michele Ruta | M | - |
Columbia Business School
| 3 Jahre |
Ameeth Sankaran | M | 47 |
Columbia Business School
| 2 Jahre |
Ron Newbold | M | - |
Columbia Business School
| 2 Jahre |
Ameenesh Shah | M | - |
Columbia Business School
| 2 Jahre |
Christopher Bartlett | M | - |
Columbia Business School
| 2 Jahre |
Luv Dinesh Parikh | M | 48 |
Columbia Business School
| 2 Jahre |
Su Hai Ji | M | 48 |
Columbia Business School
| 2 Jahre |
Hakan Ergulec | M | - |
Columbia Business School
| 2 Jahre |
Craig Billings | M | 51 |
Columbia Business School
| 2 Jahre |
Baris Brett | M | 49 |
Columbia Business School
| 2 Jahre |
Heath Terry | M | - |
Columbia Business School
| 2 Jahre |
Julia Belladonna | F | - |
Columbia Business School
| 2 Jahre |
Doron S. Eisenberg | M | - |
Columbia Business School
| 2 Jahre |
Alex S. Andrade | M | - |
Columbia Business School
| 2 Jahre |
Frederick Steindler | M | - |
Columbia Business School
| 2 Jahre |
Mark Carter | M | - |
Columbia Business School
| 2 Jahre |
Dhruv Chopra | M | 49 |
Columbia Business School
| 2 Jahre |
Jared Grusd | M | 49 |
Columbia Business School
| 2 Jahre |
Robin Singh Chhabra | M | - |
Columbia Business School
| 2 Jahre |
Brennan Hawken | M | - |
Columbia Business School
| 2 Jahre |
Edward Perkin | M | 52 |
Columbia Business School
| 2 Jahre |
Sourabh Banerji | M | - |
Columbia Business School
| 2 Jahre |
Daniel J. Gaspar | M | - |
Columbia Business School
| 2 Jahre |
Tim Mullany | M | 48 |
Columbia Business School
| 2 Jahre |
David Sgro | M | 47 |
Columbia Business School
| 2 Jahre |
Daniel Borok | M | - |
Columbia Business School
| 2 Jahre |
Eric Wilkins | M | - |
Columbia Business School
| 2 Jahre |
Nigel Winston Frankson | M | - |
Columbia Business School
| 2 Jahre |
Sunil Haren Thakor | M | - |
Columbia Business School
| 2 Jahre |
Christophe Browne | M | 46 |
Columbia Business School
| 2 Jahre |
Andrew Cavanna | M | 50 |
Columbia Business School
| 2 Jahre |
Kevin Livingston | M | 52 |
Columbia Business School
| 2 Jahre |
Trang-Thu Tran | F | - |
Columbia Business School
| 2 Jahre |
Joshua Silberstein | M | 49 |
Columbia Business School
| 2 Jahre |
Jayen Dalsukh Madia | M | - |
Columbia Business School
| 2 Jahre |
Ingrid Saukaitis Dyott | F | - |
Columbia Business School
| 2 Jahre |
Dustin K. Angelo | M | 49 |
Columbia Business School
| 2 Jahre |
Amanda Magliaro | F | - |
Columbia Business School
| 2 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 68 | 68,69% |
Israel | 31 | 31,31% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Eran Perry
- Persönliches Netzwerk